Developer docs
API playgroundTry for free, no card

Search company profiles

Seven Bridges

Full company profile

uuid0004dzp

Namestring
Seven Bridges
Legal namestring
Seven Bridges Genomics Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Seven Bridges Genomics Inc. is a privately held cloud-native bioinformatics company (now operating as part of Summa Equity-backed Velsera, formed January 12, 2023) that provides a biomedical data analysis platform serving biopharma R&D, government research agencies, academic institutions, clinical diagnostic labs, and patient advocacy organizations. The company's core product is the Seven Bridges Platform — a multi-cloud environment (AWS US, AWS EU Frankfurt, Google Cloud Platform) that supports CWL, WDL, and Nextflow workflows, Docker-based app execution via the Seven Bridges Image Registry, hosted JupyterLab and RStudio interactive analysis (Data Studio), and federated data access via GA4GH DRS-compatible interfaces. Layered on top of the platform are three specialized commercial products: GRAF (graph-based pangenome variant detection recognized as one of the most accurate INDEL callers globally), ARIA (population-scale clinico-genomic data analytics on a Snowflake data warehouse, commercially launched October 2021), and RHEO (push-button multi-omic workflow automation). The company also operates the Cancer Genomics Cloud (CGC) under NCI, hosting GDC, PDC, CDS, ICDC, and TCIA datasets.

The business model combines platform subscription and enterprise licensing (quote-based annual contracts with SSO, Divisions, and centralized billing), usage-based cloud compute and storage consumption (AWS EC2/S3 and GCP Compute Engine/GCS metered billing), professional and scientific services for biopharma and government deployments (e.g., PanCAN, NCI, UK Biobank, CareDx), managed hybrid on-premise/cloud deployments for clinical diagnostics customers, and data licensing for commercial access to ARIA-curated clinico-genomic datasets. Free academic licensing of GRAF serves as a top-of-funnel land-and-expand motion. Go-to-market is enterprise field sales with named-account targeting (Pfizer, BMS, Becton Dickinson, CareDx, DDL, NCI, UK Biobank, VA Million Veteran Program), supplemented by channel partnerships with AWS, Google Cloud, and ZS Associates. The company holds SOC 2 Type 2, SOC 3, HIPAA, ISO 27001/27017/27018, FISMA, GDPR, FDA 21 CFR Part 11, CLIA, CAP, and dbGaP Security Best Practices certifications — a compliance posture that treats all genomic data as PHI by default and serves as a primary procurement enabler for regulated buyers. Revenue and ARR are not publicly disclosed; the company has raised approximately $98 million in disclosed funding across a $3M early round (Sept 2014), $45M Series A (Feb 2016, led by Kryssen Capital), a Series B (April 2018), and a Series C initial close (April 2021), with the Series C investor undisclosed.

Short descriptiontext

Seven Bridges (now part of Velsera) is a cloud-native bioinformatics platform company serving biopharma, government, and academic institutions with genomic and clinical data analysis tools, federated datasets, and workflow automation on AWS and Google Cloud.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCharlestown, United States
HQ citystring
Charlestown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cloud bioinformatics platform, genomic data analysis, biomedical data science, next-generation sequencing workflows, population genomics software
Industry5 codes
1Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
CodeHLAGAJACPrimaryYes
2AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryNo
3Healthcare Data Lakes, Lakehouses & Cloud Warehouses
CodeHLACAIAAPrimaryNo
4Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
CodeHLAGANAIPrimaryNo
5Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
CodeHLAGAJAMPrimaryNo
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • Custom Computer Programming Services541511
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
  • Services-Computer Programming Services7371
Product category
Bioinformatics Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Platform Subscription & Enterprise Licensing
TypeSubscription Recurring
Description

Recurring platform access for enterprise customers (biopharma, government, academic institutions) with Enterprise feature tiers including Divisions, teams, centralized billing, and SSO. Enterprise features are gated behind organizational subscription agreements.

docs.sevenbridges.com
2Cloud Compute & Storage Consumption
TypeUsage Based
Description

Usage-based billing for AWS S3/GCS storage (incl. discounted archiving tier), EC2/Google Compute Engine instances, spot instance usage, and data transfer. Costs are tracked per project/billing group and visible on the Payments page.

docs.sevenbridges.com
3Professional & Scientific Services
TypeProfessional Services
Description

Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, and on-demand expert scientific support ("Meet our scientists" engagement model). Used in deployments with PanCAN, NCI, UK Biobank, and biopharma customers.

sevenbridges.com
4Managed Services (Hybrid Deployments)
TypeManaged Services
Description

Managed deployment model where Seven Bridges integrates its platform/automation with on-premise customer sequencers and environments (e.g., CareDx AlloSure 3.0 deployment) with minimal human intervention, reducing customer operational burden.

sevenbridges.com
5Data Licensing / Federated Data Access (ARIA, GRAF)
TypeLicensing Royalties
Description

Commercial access to curated population-scale clinico-genomic datasets via ARIA, plus free academic licensing of GRAF Germline Variant Detection Workflow and GRAF Pan Genome Reference (a marketing-led land-and-expand strategy into academic accounts).

sevenbridges.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Platform access: Request Access / quote-based enterprise license
ModelSubscriptionBilling cadenceAnnual
Notes

Enterprise customers enter subscription agreements; no public price point. Includes Enterprise feature set (Divisions, teams, SSO, centralized billing).

docs.sevenbridges.com
2Cloud infrastructure consumption: per-resource metered pricing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Billed per compute instance (AWS EC2 / Google Compute Engine), per storage (S3 / GCS) with reduced rate for archived files idle >3 months, and per data transfer. Spot Instances available at lower cost. Stripe handles credit card payments for individual users; Divisions support credit card payment methods.

docs.sevenbridges.com
3Free academic tier for GRAF Workflows
ModelFreemiumBilling cadencePay-as-you-go
Notes

GRAF Germline Variant Detection Workflow and GRAF Pan Genome Reference are provided free of charge to academic researchers; commercial use is a paid license.

sevenbridges.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Seven Bridges Platform
Description

Core cloud-based bioinformatics ecosystem enabling genomic and phenotypic data analysis with workflow automation, collaboration, and security features.

sevenbridges.com
+4 more records
Core offering1 text field

Seven Bridges builds and operates a cloud-native bioinformatics platform that enables researchers and organizations to organize, explore, and run genomic, multi-omic, and clinical-genomic data analyses at scale using CWL, WDL, and Nextflow workflows on AWS and Google Cloud. On top of the core platform, the company sells specialized products including ARIA (population-scale clinico-genomic data analytics), GRAF (pan-genome graph-based variant analysis), RHEO (workflow automation), and the Cancer Genomics Cloud, complemented by professional scientific services and managed hybrid deployments for biopharma, government, and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Dramatically reduced time to results for clinical workflows (CareDx AlloSure 3.0 turnaround requirements met through workflow automation)
+3 more records
Product overview1 text field

Seven Bridges is a platform-plus-modules architecture: the core offering is the Seven Bridges Platform — a cloud-based bioinformatics environment where researchers build and run workflows (CWL, WDL, Nextflow), attach cloud storage volumes, host Docker apps via the Seven Bridges Image Registry, and analyze data in Data Studio's hosted JupyterLab/RStudio instances. On top of this core platform, Seven Bridges sells several specialized modules and sub-brands: ARIA adds population-scale clinico-genomic data analytics (built on Snowflake), GRAF provides graph-based genome analysis using pangenome references, and RHEO delivers workflow automation and SDKs for production pipelines. Sister offerings include the Cancer Genomics Cloud (CGC), an NCI-flavored instance of the platform for cancer research, and the Unified Patient Network, a clinical-molecular data network for translational research.

Product and service7 records
1Seven Bridges Platform
CategoryBioinformatics Platform Software
Description

Cloud-based bioinformatics platform that enables researchers and organizations to organize, explore, and run omics data analyses through a unified environment supporting CWL, WDL, and Nextflow workflows, public and private apps, cloud storage volumes, project collaboration, and hosted JupyterLab/RStudio Data Studio instances. Targeted at biopharma R&D, government research programs, academic institutions, and clinical laboratories.

2ARIA
CategoryClinico-Genomic Data Analytics Software
Description

Population-scale clinico-genomic data analysis platform built on a Snowflake data warehouse that unlocks federated clinical-genomic datasets and integrates them with research workflows to support accelerated drug discovery for biopharma and healthcare enterprises.

3GRAF (Genome Representation and Analysis Framework)
CategoryGenomic Analysis Algorithm Software
Description

Pan-genome graph-based genome analysis engine that transforms the linear human genome reference into a genome graph, enabling large human population studies, rare disease studies using curated mutation graphs, precise de novo mutation detection via family genome graphs, and sensitive somatic mutation detection in tumors; available free for academic researchers under commercial licensing.

4RHEO (Workflow Automation)
CategoryWorkflow Automation Software
Description

Push-button multi-omic workflow automation framework that captures the entire flow from data ingress to final results, supporting visual interface (GUI), CLI, and API management with features including parallelization, conditionals, loops, and TypeScript-based automation definitions. Targeted at bioinformatics and production pipeline teams.

5Cancer Genomics Cloud (CGC)
CategoryGenomics Research Cloud Platform
Description

Cloud platform powered by Seven Bridges that hosts NIH/NCI cancer datasets (GDC, PDC, CDS, ICDC, TCIA) with two-tiered Open and Controlled access, integrated via DRS server with the Seven Bridges Platform; targeted at NCI-funded cancer researchers and consortia.

6Unified Patient Network
CategoryClinical Data Network
Description

Network product that aggregates clinical and molecular data across healthcare providers, enabling translational research and precision medicine initiatives on a harmonized dataset; targeted at biopharma R&D and healthcare enterprises.

7Professional and Scientific Bioinformatics Services
CategoryBioinformatics Professional Services
Description

Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, on-demand expert scientific support, and managed hybrid cloud/on-premise deployments (e.g., CareDx AlloSure 3.0) delivered by Seven Bridges scientists to biopharma, government, and academic customers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierMajor (International Academic Collaboration)TypeStrategic or Co-development PartnerAnnounced on2022-04-19
Description

Seven Bridges collaborated with the University of São Paulo and Google Cloud to build a Brazilian Reference Genome, combining academic expertise, cloud infrastructure, and Seven Bridges' bioinformatics platform.

Strategic tierCore (Federal Subcontractor)TypeStrategic or Co-development PartnerAnnounced on2021-09-09
Description

Selected along with Scripps Research to develop the data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID). Joint development of a federated data infrastructure for infectious disease research.

Strategic tierMajor (Consulting Channel)TypeImplementation/ SI/ Consulting PartnerAnnounced on2021-05-06
Description

ZS Associates and Seven Bridges partnered to innovate drug research and propel precision medicine. The alliance combines ZS's commercial life sciences consulting footprint with Seven Bridges' bioinformatics platform.

Strategic tierCore (Flagship Nonprofit Partner)TypeStrategic or Co-development PartnerAnnounced on2020-06-11
Description

Seven Bridges was selected by PanCAN to build a customized, integrated health data platform for pancreatic cancer research, providing researchers access to PanCAN's longitudinal clinical, genetic, and outcome data. Project goal is to evolve the data sharing paradigm and bring data from ongoing clinical trials to the research community.

Strategic tierCore (Flagship Customer-Partner)TypeStrategic or Co-development PartnerAnnounced on2020-06-09
Description

Seven Bridges announced a partnership with CareDx, Inc. (Nasdaq: CDNA) supporting the AlloSure 3.0 workflow for non-invasive kidney transplant rejection testing. Seven Bridges Platform and Automation products integrate with CareDx's on-premise sequencer and environment using a 'hybrid' automation method. Quoted: Bill Moss, CEO, Seven Bridges, called this a 'strategic scientific and bioinformatics partner' relationship.

Strategic tierFlagship (National Genomics)TypeStrategic or Co-development PartnerAnnounced on2019-06-05
Description

Seven Bridges was selected as the core informatics supplier for the UK Biobank Vanguard Phase, deploying the bioinformatics platform to support population-scale genomics research on UK Biobank data.

Strategic tierMinor (Specialty Co-Marketing)TypeStrategic or Co-development PartnerAnnounced on2018-09-11
Description

Seven Bridges & e-NIOS partnership to break the biomarker bottleneck by combining e-NIOS's clinical biomarker capabilities with Seven Bridges' bioinformatics platform and data infrastructure.

Strategic tierMajor (Academic Consortium)TypeStrategic or Co-development PartnerAnnounced on2017-10-17
Description

The Jackson Laboratory and Seven Bridges collaborated to build a centralized data platform to advance cancer research, aggregating and analyzing cancer-related datasets on the Seven Bridges platform.

Strategic tierMinor (Technology Partnership)TypeStrategic or Co-development PartnerAnnounced on2017-04-04
Description

Seven Bridges announced a strategic partnership with Spatial Transcriptomics to integrate spatial transcriptomics capabilities into the Seven Bridges bioinformatics ecosystem.

Strategic tierMajor (Federal Initiative)TypeStrategic or Co-development PartnerAnnounced on2016-06-21
Description

Seven Bridges joined the Cancer Moonshot Initiative on October 17, 2016 with a cloud platform to speed blood profiling research, and was selected to develop a Pediatrics data platform announced at the White House Precision Medicine Initiative on February 25, 2016.

Strategic tierMajor (Federal Program)TypeStrategic or Co-development PartnerAnnounced on2016-04-08
Description

The U.S. Department of Veterans Affairs collaborated with Seven Bridges to power Million Veteran Program research projects, leveraging the platform for VA-scale genomics analysis.

Strategic tierFlagship (Founding Government Program)TypeStrategic or Co-development PartnerAnnounced on2014-10-21
Description

Seven Bridges was selected by NCI on October 21, 2014 to develop the Cancer Genomics Cloud (CGC) pilot. NCI extended the scope of the pilot on October 27, 2016. The CGC hosts the Genomic Data Commons (GDC), Proteomic Data Commons (PDC), Cancer Data Service (CDS), Integrated Canine Data Commons (ICDC), and The Cancer Imaging Archive (TCIA), and is positioned as a flagship federated data ecosystem partnership.

Strategic tierMinor (Early Technology Partnership)TypeStrategic or Co-development PartnerAnnounced on2014-08-19
Description

Cellular Research and Seven Bridges partnered to offer RNA-Seq products, combining Cellular Research's assay technology with Seven Bridges' cloud bioinformatics analysis.

Strategic tierFlagship (Core Cloud Infrastructure)TypeTechnology or Integration
Description

AWS is the primary underlying IaaS for the Seven Bridges Platform. Resources used include S3 for storage and EC2 for on-demand compute. Seven Bridges has been offering genomic data processing on the AWS cloud since early 2012, processes Petabytes of data for thousands of users, holds a BAA with AWS, and runs the platform on AWS US and AWS EU (Frankfurt) regions.

Strategic tierFlagship (Core Cloud Infrastructure)TypeTechnology or Integration
Description

Google Cloud is the secondary underlying IaaS for the Seven Bridges Platform. Resources used include Google Cloud Storage (GCS) for encrypted storage and Google Compute Engine instances. Seven Bridges Platform came to Google Cloud Platform on January 19, 2016 for multi- and hybrid-cloud support.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Google Cloud's managed services for genomics pipelines and healthcare data interoperability. Comparable technical capabilities to portions of Seven Bridges' platform, with the distribution advantage of being native to the underlying cloud provider.

TypeBroad incumbent
Description

AWS-native managed bioinformatics service for genomics workflows and data. Comparable in workflow execution but built directly into the AWS substrate on which Seven Bridges runs, representing both a partner and a long-term competitive threat.

TypeBroad incumbent
Description

Sequencer vendor offering secondary analysis (DRAGEN) and cloud bioinformatics (BaseSpace) bundled with its sequencing instruments. Competes with Seven Bridges on downstream bioinformatics, with significant distribution leverage from installed sequencer base.

TypeDirect peer
Description

Genomics and clinical data platform offering federated data access, bioinformatic workflow execution, and population genomics services to pharma, healthcare, and national genomics programs. Comparable to Seven Bridges' ARIA in particular.

TypeDirect peer
Description

Cloud-based biomedical informatics platform serving biopharma, clinical diagnostics, and federal genomics customers (including NIH). Direct competitor offering similar genomics workflow execution, multi-cloud architecture, and regulated-environment compliance.

TypeEmerging player
Description

Genomic and multi-omic analysis software (Partek Flow, Partek Genomics Suite) used by academic and translational researchers. Comparable in single-cell and bulk RNA-seq analysis workflows that overlap with Seven Bridges' core platform capabilities.

TypeDirect peer
Description

Cloud genomics and bioinformatics platform with federated data access (Lifebit CloudOS) serving national genomics programs (e.g., Genomics England) and biopharma. Direct competitor in the federated genomics infrastructure category.

TypeEmerging player
Description

Clinical genomics platform combining NGS analytics, interpretation, and a federated hospital network. Comparable to Seven Bridges' clinical genomics / CareDx-style deployments, but with stronger focus on routine clinical reporting.

TypeBroad incumbent
Description

Established bioinformatics portfolio (CLC bio, Ingenuity Pathway Analysis, QIAseq) embedded within a major life-sciences tools provider. Competes with Seven Bridges in genomic analysis tools, though distributed as part of a wider wet-lab-to-software stack rather than a pure cloud bioinformatics platform.

10Terra.bio (Broad Institute / Verily)
TypeDirect peer
Description

Cloud genomics workspace co-developed by the Broad Institute and Verily on Google Cloud, serving NIH-funded researchers and consortia. Closely comparable to Seven Bridges' Cancer Genomics Cloud in target customer (NIH/NCI) and workflow execution model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers21 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seven Bridges

Bioinformatics Softwaresevenbridges.com

Seven Bridges (now part of Velsera) is a cloud-native bioinformatics platform company serving biopharma, government, and academic institutions with genomic and clinical data analysis tools, federated datasets, and workflow automation on AWS and Google Cloud.

What Seven Bridges does

Seven Bridges Genomics Inc. is a privately held cloud-native bioinformatics company (now operating as part of Summa Equity-backed Velsera, formed January 12, 2023) that provides a biomedical data analysis platform serving biopharma R&D, government research agencies, academic institutions, clinical diagnostic labs, and patient advocacy organizations. The company's core product is the Seven Bridges Platform — a multi-cloud environment (AWS US, AWS EU Frankfurt, Google Cloud Platform) that supports CWL, WDL, and Nextflow workflows, Docker-based app execution via the Seven Bridges Image Registry, hosted JupyterLab and RStudio interactive analysis (Data Studio), and federated data access via GA4GH DRS-compatible interfaces. Layered on top of the platform are three specialized commercial products: GRAF (graph-based pangenome variant detection recognized as one of the most accurate INDEL callers globally), ARIA (population-scale clinico-genomic data analytics on a Snowflake data warehouse, commercially launched October 2021), and RHEO (push-button multi-omic workflow automation). The company also operates the Cancer Genomics Cloud (CGC) under NCI, hosting GDC, PDC, CDS, ICDC, and TCIA datasets.

The business model combines platform subscription and enterprise licensing (quote-based annual contracts with SSO, Divisions, and centralized billing), usage-based cloud compute and storage consumption (AWS EC2/S3 and GCP Compute Engine/GCS metered billing), professional and scientific services for biopharma and government deployments (e.g., PanCAN, NCI, UK Biobank, CareDx), managed hybrid on-premise/cloud deployments for clinical diagnostics customers, and data licensing for commercial access to ARIA-curated clinico-genomic datasets. Free academic licensing of GRAF serves as a top-of-funnel land-and-expand motion. Go-to-market is enterprise field sales with named-account targeting (Pfizer, BMS, Becton Dickinson, CareDx, DDL, NCI, UK Biobank, VA Million Veteran Program), supplemented by channel partnerships with AWS, Google Cloud, and ZS Associates. The company holds SOC 2 Type 2, SOC 3, HIPAA, ISO 27001/27017/27018, FISMA, GDPR, FDA 21 CFR Part 11, CLIA, CAP, and dbGaP Security Best Practices certifications — a compliance posture that treats all genomic data as PHI by default and serves as a primary procurement enabler for regulated buyers. Revenue and ARR are not publicly disclosed; the company has raised approximately $98 million in disclosed funding across a $3M early round (Sept 2014), $45M Series A (Feb 2016, led by Kryssen Capital), a Series B (April 2018), and a Series C initial close (April 2021), with the Series C investor undisclosed.

Seven Bridges firmographics

Firmographics
Name
Seven Bridges
Legal name
Seven Bridges Genomics Inc.
Website
https://sevenbridges.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
251–500 employees
Short description
Seven Bridges (now part of Velsera) is a cloud-native bioinformatics platform company serving biopharma, government, and academic institutions with genomic and clinical data analysis tools, federated datasets, and workflow automation on AWS and Google Cloud.
Ownership category
akta.pro rank

Seven Bridges industry classification

Industry
Product category
Bioinformatics Software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
akta.pro primary industry
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
akta.pro secondary industries
AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Healthcare Data Lakes, Lakehouses & Cloud Warehouses (HLACAIAA), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

  • Cloud bioinformatics platform
  • Genomic data analysis
  • Biomedical data science
  • Next-generation sequencing workflows
  • Population genomics software

Where Seven Bridges is headquartered

Location

Headquarters

HQ city
Charlestown
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Seven Bridges business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Subscription & Enterprise Licensing: Recurring platform access for enterprise customers (biopharma, government, academic institutions) with Enterprise feature tiers including Divisions, teams, centralized billing, and SSO. Enterprise features are gated behind organizational subscription agreements.
  2. Cloud Compute & Storage Consumption: Usage-based billing for AWS S3/GCS storage (incl. discounted archiving tier), EC2/Google Compute Engine instances, spot instance usage, and data transfer. Costs are tracked per project/billing group and visible on the Payments page.
  3. Professional & Scientific Services: Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, and on-demand expert scientific support ("Meet our scientists" engagement model). Used in deployments with PanCAN, NCI, UK Biobank, and biopharma customers.
  4. Managed Services (Hybrid Deployments): Managed deployment model where Seven Bridges integrates its platform/automation with on-premise customer sequencers and environments (e.g., CareDx AlloSure 3.0 deployment) with minimal human intervention, reducing customer operational burden.
  5. Data Licensing / Federated Data Access (ARIA, GRAF): Commercial access to curated population-scale clinico-genomic datasets via ARIA, plus free academic licensing of GRAF Germline Variant Detection Workflow and GRAF Pan Genome Reference (a marketing-led land-and-expand strategy into academic accounts).

Pricing tiers

ModelBillingPrice
SubscriptionAnnualPlatform access: Request Access / quote-based enterprise license
Usage-basedPay-as-you-goCloud infrastructure consumption: per-resource metered pricing
FreemiumPay-as-you-goFree academic tier for GRAF Workflows

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Seven Bridges product offering

Product offering

Core offering

Seven Bridges builds and operates a cloud-native bioinformatics platform that enables researchers and organizations to organize, explore, and run genomic, multi-omic, and clinical-genomic data analyses at scale using CWL, WDL, and Nextflow workflows on AWS and Google Cloud. On top of the core platform, the company sells specialized products including ARIA (population-scale clinico-genomic data analytics), GRAF (pan-genome graph-based variant analysis), RHEO (workflow automation), and the Cancer Genomics Cloud, complemented by professional scientific services and managed hybrid deployments for biopharma, government, and academic customers.

Product overview

Seven Bridges is a platform-plus-modules architecture: the core offering is the Seven Bridges Platform — a cloud-based bioinformatics environment where researchers build and run workflows (CWL, WDL, Nextflow), attach cloud storage volumes, host Docker apps via the Seven Bridges Image Registry, and analyze data in Data Studio's hosted JupyterLab/RStudio instances. On top of this core platform, Seven Bridges sells several specialized modules and sub-brands: ARIA adds population-scale clinico-genomic data analytics (built on Snowflake), GRAF provides graph-based genome analysis using pangenome references, and RHEO delivers workflow automation and SDKs for production pipelines. Sister offerings include the Cancer Genomics Cloud (CGC), an NCI-flavored instance of the platform for cancer research, and the Unified Patient Network, a clinical-molecular data network for translational research.

Differentiator

Problem solved

Functional benefit

Brands

  • Seven Bridges Platform: Core cloud-based bioinformatics ecosystem enabling genomic and phenotypic data analysis with workflow automation, collaboration, and security features.
  • ARIA
  • GRAF
  • RHEO
  • Velsera

Products and services

  • Seven Bridges Platform Cloud-based bioinformatics platform that enables researchers and organizations to organize, explore, and run omics data analyses through a unified environment supporting CWL, WDL, and Nextflow workflows, public and private apps, cloud storage volumes, project collaboration, and hosted JupyterLab/RStudio Data Studio instances. Targeted at biopharma R&D, government research programs, academic institutions, and clinical laboratories.
  • ARIA Population-scale clinico-genomic data analysis platform built on a Snowflake data warehouse that unlocks federated clinical-genomic datasets and integrates them with research workflows to support accelerated drug discovery for biopharma and healthcare enterprises.
  • GRAF (Genome Representation and Analysis Framework) Pan-genome graph-based genome analysis engine that transforms the linear human genome reference into a genome graph, enabling large human population studies, rare disease studies using curated mutation graphs, precise de novo mutation detection via family genome graphs, and sensitive somatic mutation detection in tumors; available free for academic researchers under commercial licensing.
  • RHEO (Workflow Automation) Push-button multi-omic workflow automation framework that captures the entire flow from data ingress to final results, supporting visual interface (GUI), CLI, and API management with features including parallelization, conditionals, loops, and TypeScript-based automation definitions. Targeted at bioinformatics and production pipeline teams.
  • Cancer Genomics Cloud (CGC) Cloud platform powered by Seven Bridges that hosts NIH/NCI cancer datasets (GDC, PDC, CDS, ICDC, TCIA) with two-tiered Open and Controlled access, integrated via DRS server with the Seven Bridges Platform; targeted at NCI-funded cancer researchers and consortia.
  • Unified Patient Network Network product that aggregates clinical and molecular data across healthcare providers, enabling translational research and precision medicine initiatives on a harmonized dataset; targeted at biopharma R&D and healthcare enterprises.
  • Professional and Scientific Bioinformatics Services Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, on-demand expert scientific support, and managed hybrid cloud/on-premise deployments (e.g., CareDx AlloSure 3.0) delivered by Seven Bridges scientists to biopharma, government, and academic customers.

Quantifiable outcome

  • Dramatically reduced time to results for clinical workflows (CareDx AlloSure 3.0 turnaround requirements met through workflow automation)
  • +3 more outcomes

Companies that use Seven Bridges

Customer profile

Named customers21 records

Segments5 records

Ideal customer profiles4 records

Seven Bridges technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

Feature10 records

Seven Bridges partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major (international academic collaboration), core (federal subcontractor), major (consulting channel), core (flagship nonprofit partner), core (flagship customer-partner), flagship (national genomics), minor (specialty co-marketing), major (academic consortium), minor (technology partnership), major (federal initiative), major (federal program), flagship (founding government program), minor (early technology partnership) and flagship (core cloud infrastructure).

  • University of São Paulomajor (international academic collaboration)Strategic or Co-development Partner · 19 April 2022Seven Bridges collaborated with the University of São Paulo and Google Cloud to build a Brazilian Reference Genome, combining academic expertise, cloud infrastructure, and Seven Bridges' bioinformatics platform.
  • Scripps Researchcore (federal subcontractor)Strategic or Co-development Partner · 9 September 2021Selected along with Scripps Research to develop the data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID). Joint development of a federated data infrastructure for infectious disease research.
  • ZS Associatesmajor (consulting channel)Implementation/ SI/ Consulting Partner · 6 May 2021ZS Associates and Seven Bridges partnered to innovate drug research and propel precision medicine. The alliance combines ZS's commercial life sciences consulting footprint with Seven Bridges' bioinformatics platform.
  • Pancreatic Cancer Action Network (PanCAN)core (flagship nonprofit partner)Strategic or Co-development Partner · 11 June 2020Seven Bridges was selected by PanCAN to build a customized, integrated health data platform for pancreatic cancer research, providing researchers access to PanCAN's longitudinal clinical, genetic, and outcome data. Project goal is to evolve the data sharing paradigm and bring data from ongoing clinical trials to the research community.
  • CareDxcore (flagship customer-partner)Strategic or Co-development Partner · 9 June 2020Seven Bridges announced a partnership with CareDx, Inc. (Nasdaq: CDNA) supporting the AlloSure 3.0 workflow for non-invasive kidney transplant rejection testing. Seven Bridges Platform and Automation products integrate with CareDx's on-premise sequencer and environment using a 'hybrid' automation method. Quoted: Bill Moss, CEO, Seven Bridges, called this a 'strategic scientific and bioinformatics partner' relationship.
  • UK Biobankflagship (national genomics)Strategic or Co-development Partner · 5 June 2019Seven Bridges was selected as the core informatics supplier for the UK Biobank Vanguard Phase, deploying the bioinformatics platform to support population-scale genomics research on UK Biobank data.
  • e-NIOSminor (specialty co-marketing)Strategic or Co-development Partner · 11 September 2018Seven Bridges & e-NIOS partnership to break the biomarker bottleneck by combining e-NIOS's clinical biomarker capabilities with Seven Bridges' bioinformatics platform and data infrastructure.
  • The Jackson Laboratorymajor (academic consortium)Strategic or Co-development Partner · 17 October 2017The Jackson Laboratory and Seven Bridges collaborated to build a centralized data platform to advance cancer research, aggregating and analyzing cancer-related datasets on the Seven Bridges platform.
  • Spatial Transcriptomicsminor (technology partnership)Strategic or Co-development Partner · 4 April 2017Seven Bridges announced a strategic partnership with Spatial Transcriptomics to integrate spatial transcriptomics capabilities into the Seven Bridges bioinformatics ecosystem.
  • Cancer Moonshot Initiativemajor (federal initiative)Strategic or Co-development Partner · 21 June 2016Seven Bridges joined the Cancer Moonshot Initiative on October 17, 2016 with a cloud platform to speed blood profiling research, and was selected to develop a Pediatrics data platform announced at the White House Precision Medicine Initiative on February 25, 2016.
  • U.S. Department of Veterans Affairs - Million Veteran Programmajor (federal program)Strategic or Co-development Partner · 8 April 2016The U.S. Department of Veterans Affairs collaborated with Seven Bridges to power Million Veteran Program research projects, leveraging the platform for VA-scale genomics analysis.
  • National Cancer Institute (NCI)flagship (founding government program)Strategic or Co-development Partner · 21 October 2014Seven Bridges was selected by NCI on October 21, 2014 to develop the Cancer Genomics Cloud (CGC) pilot. NCI extended the scope of the pilot on October 27, 2016. The CGC hosts the Genomic Data Commons (GDC), Proteomic Data Commons (PDC), Cancer Data Service (CDS), Integrated Canine Data Commons (ICDC), and The Cancer Imaging Archive (TCIA), and is positioned as a flagship federated data ecosystem partnership.
  • Cellular Researchminor (early technology partnership)Strategic or Co-development Partner · 19 August 2014Cellular Research and Seven Bridges partnered to offer RNA-Seq products, combining Cellular Research's assay technology with Seven Bridges' cloud bioinformatics analysis.
  • Amazon Web Services (AWS)flagship (core cloud infrastructure)Technology or IntegrationAWS is the primary underlying IaaS for the Seven Bridges Platform. Resources used include S3 for storage and EC2 for on-demand compute. Seven Bridges has been offering genomic data processing on the AWS cloud since early 2012, processes Petabytes of data for thousands of users, holds a BAA with AWS, and runs the platform on AWS US and AWS EU (Frankfurt) regions.
  • Google Cloud Platform (GCP)flagship (core cloud infrastructure)Technology or IntegrationGoogle Cloud is the secondary underlying IaaS for the Seven Bridges Platform. Resources used include Google Cloud Storage (GCS) for encrypted storage and Google Compute Engine instances. Seven Bridges Platform came to Google Cloud Platform on January 19, 2016 for multi- and hybrid-cloud support.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Seven Bridges competitors and assessment

Company assessment

Broad incumbents

  • Google Cloud Life Sciences / Cloud Healthcare API: Google Cloud's managed services for genomics pipelines and healthcare data interoperability. Comparable technical capabilities to portions of Seven Bridges' platform, with the distribution advantage of being native to the underlying cloud provider.
  • Amazon Web Services HealthOmics: AWS-native managed bioinformatics service for genomics workflows and data. Comparable in workflow execution but built directly into the AWS substrate on which Seven Bridges runs, representing both a partner and a long-term competitive threat.
  • Illumina (BaseSpace Sequence Hub, DRAGEN): Sequencer vendor offering secondary analysis (DRAGEN) and cloud bioinformatics (BaseSpace) bundled with its sequencing instruments. Competes with Seven Bridges on downstream bioinformatics, with significant distribution leverage from installed sequencer base.
  • QIAGEN Digital Insights (formerly QIAGEN Bioinformatics): Established bioinformatics portfolio (CLC bio, Ingenuity Pathway Analysis, QIAseq) embedded within a major life-sciences tools provider. Competes with Seven Bridges in genomic analysis tools, though distributed as part of a wider wet-lab-to-software stack rather than a pure cloud bioinformatics platform.

Direct peers

  • BC Platforms: Genomics and clinical data platform offering federated data access, bioinformatic workflow execution, and population genomics services to pharma, healthcare, and national genomics programs. Comparable to Seven Bridges' ARIA in particular.
  • DNAnexus: Cloud-based biomedical informatics platform serving biopharma, clinical diagnostics, and federal genomics customers (including NIH). Direct competitor offering similar genomics workflow execution, multi-cloud architecture, and regulated-environment compliance.
  • Lifebit Biotech: Cloud genomics and bioinformatics platform with federated data access (Lifebit CloudOS) serving national genomics programs (e.g., Genomics England) and biopharma. Direct competitor in the federated genomics infrastructure category.
  • Terra.bio (Broad Institute / Verily): Cloud genomics workspace co-developed by the Broad Institute and Verily on Google Cloud, serving NIH-funded researchers and consortia. Closely comparable to Seven Bridges' Cancer Genomics Cloud in target customer (NIH/NCI) and workflow execution model.

Emerging players

  • Partek (now part of Illumina): Genomic and multi-omic analysis software (Partek Flow, Partek Genomics Suite) used by academic and translational researchers. Comparable in single-cell and bulk RNA-seq analysis workflows that overlap with Seven Bridges' core platform capabilities.
  • SOPHiA GENETICS: Clinical genomics platform combining NGS analytics, interpretation, and a federated hospital network. Comparable to Seven Bridges' clinical genomics / CareDx-style deployments, but with stronger focus on routine clinical reporting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Seven Bridges social profiles

Digital presence

Seven Bridges compliance and trust

Trust signal

Compliance12 records

Seven Bridges financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seven Bridges leadership team

Management profile

Number of profiles

Profiles9 records

Seven Bridges subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Seven Bridges funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seven Bridges M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seven Bridges

What does Seven Bridges do?

Seven Bridges builds and operates a cloud-native bioinformatics platform that enables researchers and organizations to organize, explore, and run genomic, multi-omic, and clinical-genomic data analyses at scale using CWL, WDL, and Nextflow workflows on AWS and Google Cloud. On top of the core platform, the company sells specialized products including ARIA (population-scale clinico-genomic data analytics), GRAF (pan-genome graph-based variant analysis), RHEO (workflow automation), and the Cancer Genomics Cloud, complemented by professional scientific services and managed hybrid deployments for biopharma, government, and academic customers.

Is Seven Bridges a public or private company?

Seven Bridges is a private company. It is classified as private equity controlled and is currently operating.

When was Seven Bridges founded?

Seven Bridges was founded in 2009. It employs 251 to 500 people.

Where is Seven Bridges based?

Seven Bridges is headquartered in Charlestown, United States, in the North America region.

How does Seven Bridges make money?

Five revenue lines are on record. Platform Subscription & Enterprise Licensing is the primary driver. The others are cloud Compute & Storage Consumption, professional & Scientific Services, managed Services (Hybrid Deployments) and data Licensing / Federated Data Access (ARIA, GRAF).

Who are Seven Bridges's main competitors?

Broad incumbents on record are Google Cloud Life Sciences / Cloud Healthcare API, Amazon Web Services HealthOmics, Illumina (BaseSpace Sequence Hub, DRAGEN) and QIAGEN Digital Insights (formerly QIAGEN Bioinformatics). Direct peers are BC Platforms, DNAnexus, Lifebit Biotech and Terra.bio (Broad Institute / Verily). Emerging players are Partek (now part of Illumina) and SOPHiA GENETICS.

Does Seven Bridges have an API?

Yes. Seven Bridges provides a public REST API that lets developers programmatically manage bioinformatics projects, apps, files, tasks, and volumes. The platform supports authentication via authentication token, and exposes libraries/SDKs in Python, R, and Java, plus a Command Line Interface (CLI). A documented API rate limit applies. Developer documentation is at docs.sevenbridges.com/docs/the-api.

What industry is Seven Bridges in?

Seven Bridges's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MediumWhy your investment in self-service bioinformatics software was a mistake and where to invest next in TechBioThe article argues that generic commercial self-service bioinformatics software is a flawed investment due to the non-standard nature of data preprocessing and significant customer heterogeneity. It cites companies such as Lifebit, Seven Bridges, and LatchBio as examples where capital failed to create universal tools, leading many to pivot toward consultancy models or narrow their scope.SanogeneticsThe principle of precision: Why navigating the nuances in genetic test interpretation is more important than everThe article discusses the complexities and risks associated with interpreting genetic test results, highlighting issues such as false positives in Direct-to-Consumer (DTC) testing and the critical importance of accurate variant classification. It cites a legal case involving a genetics laboratory's misinterpretation of the SCN1A gene as a key example of the severe consequences of diagnostic errors. The text emphasizes the growing role of bioinformatics platforms like Terra and Seven Bridges in processing genomic data to improve clinical outcomes.GenomeWebPierian, Seven Bridges, UgenTec Acquired, Merged to Become VelseraInvestment fund Summa Equity has acquired Pierian, Seven Bridges, and UgenTec to merge them into a new precision medicine company named Velsera. The transaction was announced at the JP Morgan Healthcare Conference, with Boston-based Velsera now led by CEO Gavin Nichols. The combined entity aims to integrate software platforms and domain expertise to accelerate omics data insights in clinical and research settings.PR NewswireSeven Bridges Expands Platform to Support Execution of Nextflow and WDL WorkflowsSeven Bridges, a Boston-based bioinformatics ecosystem provider, announced the expansion of its platform to support Nextflow and WDL workflows alongside its existing CWL support, enabling researchers to use their preferred workflow language in a secure, compliant, collaborative environment. The platform now offers more than 600 optimized CWL workflows and provides access to large repositories of WDL and Nextflow workflows, as well as in-house developed workflows. The company stated this expansion, combined with its multi-cloud capabilities, aims to advance precision medicine by enabling researchers worldwide to generate insights from large biomedical datasets.PR NewswireSeven Bridges and Scripps Research Selected to Develop Data Ecosystem for the National Institute of Allergy and Infectious DiseasesSeven Bridges and Scripps Research have been awarded a $7.5 million contract to develop the NIAID Data Ecosystem (NDE) for the National Institute of Allergy and Infectious Diseases. The project aims to create a secure, federated environment that allows researchers to discover, access, and analyze data from various NIAID repositories to better respond to infectious diseases and future pandemics.PR NewswireSeven Bridges Names David J. Ramos Chief Technology OfficerSeven Bridges, a Boston-based bioinformatics ecosystem provider, announced the appointment of David J. Ramos as Chief Technology Officer. Ramos previously led engineering for the CVS HealthCloud platform and brings over a decade of product and engineering leadership experience from companies including Rakuten, Oracle, KPMG, and PwC. In his new role, Ramos will lead Seven Bridges' technology organization and oversee their cloud-native bioinformatics R&D ecosystem that serves academic, biotechnology, pharmaceutical, and government research entities.PR NewswireSeven Bridges Earns 2021 Frost & Sullivan Global Enabling Technology Leadership AwardSeven Bridges, a Boston-based bioinformatics ecosystem provider, has been recognized by Frost & Sullivan as the 2021 Global Enabling Technology Leader for its precision medicine informatics platform. Frost & Sullivan's analysis highlighted the platform's secure collaboration features, data interoperability, scalability, and the GRAF solution for genomic analyses as key differentiating factors. The award recognizes Seven Bridges' role in enabling researchers at academic, biotech, pharmaceutical, and clinical entities to advance precision medicine through cloud-based data analysis.PR NewswireZS and Seven Bridges Partner to Innovate Drug Research and Propel Precision MedicineZS and Seven Bridges announced a strategic partnership on May 6, 2021, combining ZS's biomedical research services and data science expertise with Seven Bridges' multi-omics analytics technology platform to provide biopharmaceutical and biotechnology companies with an integrated solution for drug discovery and translational medicine. The collaboration aims to help clients accelerate drug development, analyze molecular and genomic data, and increase the probability of success for new drug candidates by addressing growing multi-omics data and analytics needs. Through this partnership, both companies seek to build scalable solutions leveraging ZS's consulting teams and research data lake alongside Seven Bridges' ARIATM platform.PR NewswireSeven Bridges Announces Initial Close of Series C Funding from New Strategic Investor to Accelerate Product Development and Commercial GrowthSeven Bridges, a bioinformatics ecosystem provider, announced on April 27, 2021 the close of the first $15 million of a planned $30 million Series C from a new life sciences investor. The company said the funding will support product development and commercial growth, and the investor will join an expanded board of directors. Seven Bridges expects to fully close the round in the second quarter.PR NewswireSeven Bridges Launches the GRAF™ Population Solution -- Population-Specific Tools and Services to Enhance Genetic Variation DiscoverySeven Bridges, a Boston-based bioinformatics ecosystem provider, announced the launch of the GRAF™ Population Solution, a set of population-specific workflows, services, and graph references for five major global populations to improve genetic variation discovery in human genomics research. The solution addresses inherent bias in current linear reference genomes that favor European populations by providing ancestry-aware bioinformatics tools, claiming a 50% reduction in alignment errors and a 10% increase in variant calling sensitivity. The company positions the launch as advancing precision medicine by enabling more accurate genomic research for under-represented populations including African, East Asian, South Asian, and Admixed American groups.